Amnion-Derived Stem Cells for Regenerative Medicine
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current stem cell therapies face challenges with ethical concerns, immunological compatibility, and safety issues, particularly with embryonic stem cells, while adult stem cells' plasticity is controversial and their survival in transplantation is questionable, necessitating the development of alternative stem cell sources for regenerative medicine.
Innovation Solution
The method involves isolating and characterizing amnion-derived stem cells (ADSCs) from the amniotic membrane, which are cultured and cryopreserved, demonstrating multipotency and pluripotency, and capable of differentiating into various cell types, thus offering a viable alternative for cell replacement therapies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If embryonic stem cells are used for cell replacement therapy, then pluripotency and self-renewal capabilities are achieved, but ethical concerns and immunological incompatibility issues arise
Solution Approach 1:
The invention segments the placental tissue into distinct cellular components, specifically isolating amniotic epithelial cells from the chorionic tissue. This segmentation allows obtaining stem cells with pluripotent characteristics from a non-controversial source (placenta) rather than using embryonic tissues, thereby resolving the ethical concerns while maintaining the desired pluripotency capability
Solution Approach 2:
The invention uses placental tissue as an intermediary source that bridges the gap between embryonic stem cells (which have pluripotency but ethical issues) and adult stem cells (which have ethical acceptance but limited plasticity). The amniotic epithelial cells derived from placenta serve as a mediator that exhibits ES cell-like pluripotency and self-renewal capabilities without the ethical controversies associated with embryonic stem cells
2Object-affected harmful factors
If adult stem cells are used for therapy, then ethical concerns are avoided, but plasticity and differentiation capability are limited
Solution Approach 1:
The invention creates a copy of embryonic stem cell characteristics (pluripotency, self-renewal, undifferentiated state) using amniotic epithelial cells from placental tissue. These cells replicate the desirable properties of ES cells without requiring actual embryonic tissues, thus providing an ethical alternative that maintains full plasticity and differentiation capability comparable to embryonic stem cells
3Productivity
If embryonic stem cells are transplanted, then cell replacement is achieved, but tumor formation risk increases
Solution Approach 1:
The invention employs amniotic epithelial cells from placenta that can be cultured and expanded extensively in vitro before transplantation. These cells can be prepared as needed, allowing for quality control and characterization to ensure they are free from tumorigenic potential, whereas embryonic stem cells require ongoing complex culture maintenance that increases tumor formation risks
4Object-affected harmful factors
If adult stem cells are transplanted, then immunological compatibility is improved, but cell survival and long-term function are questionable
Solution Approach 1:
The invention performs preliminary expansion and characterization of amniotic epithelial cells in culture before transplantation. This allows for selecting and preparing cells with optimal properties for transplantation, ensuring both immunological compatibility and long-term survival capability. The cells can be pre-tested for functionality and stability, providing reliable, long-lasting therapeutic effects
Data Source
Figure 1A~1B
Figure 2A~2F
Figure 3A~3F
AI summary
The present invention relates to stem cells obtained from the amnion and their methods of obtaining and culturing. The present invention further relates to compositions comprising amnion-derived stems cells (ADSCs) and to methods of using ADSCs.